Analyst Matthew Harrison from Morgan Stanley reckons November to be the most possible time for all three leading vaccines to have definitive effectiveness data. He is certain that the data could be introduced even this month, but only in case of high vaccine effectiveness.

He claims that Pfizer may think that its vaccine effectiveness is at least 70% as the corporation stated earlier that it plans to submit data to regulators by the end of the third quarter in October. 

Harrison argues that in case the FDA places a high bar for an emergency use authorization, we shouldn’t expect a regulatory filing until late November, he warns.